Cayetano Heredia Peruvian University

www.upch.edu.pe
Lima, Peru

Cayetano Heredia University is a private university located in Lima, Peru. It was named in honor of Cayetano Heredia, one of the eminent Peruvian physicians of the 19th century. The university is overseen by a Board of Trustees and is not actually property of any private or state entity. It is considered one of the top medical schools in Peru, and is currently the major publisher of scientific articles in the country. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.2.3.2-2 | Award Amount: 7.87M | Year: 2013

Diabetes (DM) triples the risk of developing tuberculosis (TB). Consequently, the alarming growth of type 2 DM in TB endemic countries and among people originating from TB-endemic countries poses a serious threat to global TB control. This project addresses the scarce evidence for many of the recently advocated guidelines for care and control of TB and DM, as well as our lack of understanding of the mechanisms underlying the effect of DM on TB susceptibility and treatment outcome. We will use a comprehensive and integrated approach combining clinical, epidemiological and cutting edge expertise in laboratory sciences, bringing together a multi-disciplinary consortium linking field sites in Romania, Peru, South Africa and Indonesia, with leading laboratories in Germany, United Kingdom and the Netherlands. We will define the optimal and most cost-effective ways of screening TB patients for DM diabetes, and determine the prevalence of DM among TB patients and of TB in DM patients in the four countries. With regard to treatment, we will determine the level of DM management required during and after TB treatment, the safety and pharmacokinetics of metformin when combined with rifampicin, and the effect of hyperglycemia control on TB treatment outcome. To help establish the cellular basis and immunological pathways underlying the link between DM and TB we will provide new data on: gene expression data of TB patients with and without DM; ex vivo and in vitro Mycobacterium tuberculosis stimulation data of different cell types, including macrophage subsets and adipocytes in the presence of high glucose and insulin; data regarding the role of common and more rare genetic variants in the combined susceptibility to TB and type 2 DM; and relevant functional genomics experiments. In summary, this project is expected to have significant impact both in improving basic knowledge on the link between TB and DM, as well as on prevention, therapeutic management and prognosis of TB-DM.


Mahanty S.,National Institute of Allergy and Infectious Diseases | Garcia H.H.,Cayetano Heredia Peruvian University | Garcia H.H.,Institute Ciencias Neurologicas
Progress in Neurobiology | Year: 2010

Taenia solium cysticercosis is still a major cause of seizures around the world. Despite an extensive body of published literature on this topic, knowledge of the biology, immunology, pathophysiology, and treatment of this parasite remains largely incomplete. This review summarizes recent information on the biology, clinical manifestations, immunopathology treatment and control of this important and neglected zoonotic disease, with emphasis on areas where recent developments have changed traditional and established views. © 2009 Elsevier Ltd.


Grant
Agency: European Commission | Branch: FP7 | Program: CSA | Phase: ICT-2011.5.5 | Award Amount: 982.00K | Year: 2011

The project Mobile Inclusion Platform for Europe and Latin America (M-Inclusion) is a Support Action funded by the European Commission whose overall objective is to create a cooperation framework between EU and LATAM mobile solution developers and different entities (e.g., public bodies, Third Sector associations) voicing the digital inclusion needs of people at risk of exclusion in LATAM in order to improve their personal autonomy, and through that, their social integration.\nM-Inclusion is based on:\na) Project Consortium comprising different type of actors (4 EU, 3 LATAM) bringing different capabilities, knowledge, experience and network to major initiatives and services in the field\nb) M-Inclusions innovative approach taking the end-users input representatives as initial reference for work and setting hybrid work groups to build the final M-Inclusion Roadmap.\nc) A stakeholder group comprised with at least 30 organizations involved in solving the inclusion problems for the target groups identified\nd) An innovative IT Web Portal\nAll interested actors will integrate the M-Inclusion Community, an open forum for dialogue supported by the IT Web Portal, offering:\n1) Complete data base with references, resources, organizations, success cases, technologies; all about mobile technologies for personal autonomy and social inclusion\n2) A work environment for defining the M-Inclusion Roadmap. A detailed guide containing: the needs of the identified end users, suitable technological solutions, future technological trends and recommended actions in order to fully tackle social inclusion objectives.\n3) Support through a specific tool (Open Funding Platform), and related services to the identification and promotion of RTD projects based on the Open Innovation concept (collaborative RTD);\n4) Support to market opportunity generation through two M-Inclusion Ideas Competitions (Challenges) and a M-Inclusion Marketplace that will help developers display their mobile applications, web services and ideas related to inclusion into the market, and will be linked with existing relevant platforms supporting developers, such as Telefnicas Blue Via or Nokias Open Forum, amongst other possibilities.\nThe project promotes both a working environment to define a Mobile Inclusion solutions Road Map and the growth of innovative, user-oriented, and affordable mobile solutions. In order to do this, M-Inclusion will actively incorporate, within the process, representatives of four groups of potential end-users: people with disabilities, chronic patients, low-income sectors and population from isolated areas, in order to fully understand their specific needs and handicaps. Besides, the project intends to contribute to the digital breach debate, sharing recommendations and conclusions with representatives of the IT industry and public bodies with responsibility in national and regional digital agendas through dissemination activities.


Salazar C.A.,Cayetano Heredia Peruvian University
The Cochrane database of systematic reviews | Year: 2014

Chronic anticoagulation with vitamin K antagonists (VKAs) prevents ischaemic stroke and systemic embolism in people with non-valvular atrial fibrillation (AF) but dose adjustment, coagulation monitoring and bleeding limits its use. Direct thrombin inhibitors (DTIs) are under investigation as potential alternatives. To assess (1) the comparative efficacy of long-term anticoagulation using DTIs versus VKAs on vascular deaths and ischaemic events in people with non-valvular AF, and (2) the comparative safety of chronic anticoagulation using DTIs versus VKAs on (a) fatal and non-fatal major bleeding events including haemorrhagic strokes, (b) adverse events other than bleeding and ischaemic events that lead to treatment discontinuation and (c) all-cause mortality in people with non-valvular AF. We searched the Cochrane Stroke Group Trials Register (July 2013), the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, May 2013), MEDLINE (1950 to July 2013), EMBASE (1980 to October 2013), LILACS (1982 to October 2013) and trials registers (September 2013). We also searched the websites of clinical trials and pharmaceutical companies and handsearched the reference lists of articles and conference proceedings. Randomised controlled trials (RCTs) comparing DTIs versus VKAs for prevention of stroke and systemic embolism in people with non-valvular AF. All three review authors independently performed data extraction and assessment of risk of bias. Primary analyses compared all DTIs combined versus warfarin. We performed post hoc analyses excluding ximelagatran because this drug was withdrawn from the market owing to safety concerns. We included eight studies involving a total of 27,557 participants with non-valvular AF and one or more risk factors for stroke; 26,601 of them were assigned to standard doses groups and included in the primary analysis. The DTIs: dabigatran 110 mg twice daily and 150 mg twice daily (three studies, 12,355 participants), AZD0837 300 mg once per day (two studies, 233 participants) and ximelagatran 36 mg twice per day (three studies, 3726 participants) were compared with the VKA warfarin (10,287 participants). Overall risk of bias and statistical heterogeneity of the studies included were low.The odds of vascular death and ischaemic events were not significantly different between all DTIs and warfarin (odds ratio (OR) 0.94, 95% confidence interval (CI) 0.85 to 1.05). Sensitivity analysis by dose of dabigatran on reduction in ischaemic events and vascular mortality indicated that dabigatran 150 mg twice daily was superior to warfarin although the effect estimate was of borderline statistical significance (OR 0.86, 95% CI 0.75 to 0.99). Sensitivity analyses by other factors did not alter the results. Fatal and non-fatal major bleeding events, including haemorrhagic strokes, were less frequent with the DTIs (OR 0.87, 95% CI 0.78 to 0.97). Adverse events that led to discontinuation of treatment were significantly more frequent with the DTIs (OR 2.18, 95% CI 1.82 to 2.61). All-cause mortality was similar between DTIs and warfarin (OR 0.91, 95% CI 0.83 to 1.01). DTIs were as efficacious as VKAs for the composite outcome of vascular death and ischaemic events and only the dose of dabigatran 150 mg twice daily was found to be superior to warfarin. DTIs were associated with fewer major haemorrhagic events, including haemorrhagic strokes. Adverse events that led to discontinuation of treatment occurred more frequently with the DTIs. We detected no difference in death from all causes.


Patent
Cayetano Heredia Peruvian University, San Fernando S.A. and Institute Of Recherche Pour Le Developpement | Date: 2012-11-09

The invention is referring to an essential oil from lemon peel useful as growth promoter in poultry, such composition comprises at least 16.84 to 46.12% of D-Limonene; 5.67 to 19.86% of y-Terpinene; 4.27 to 12.13% of Terpinolene; 4.60 to 14.75% of p-Ment-1-en-8-ol; among other components. The invention also refers to a poultry food supplement, which comprises 1 kg per metric ton of food from such composition of essential oil.


Grant
Agency: GTR | Branch: MRC | Program: | Phase: Research Grant | Award Amount: 195.09K | Year: 2014

People with epilepsy suffer from lack of treatment. Free drug treatment will improve many lives at very low cost for governments. This trial will demonstrate the cost benefit of such a policy and change the lives of thousands of people and their families


Grant
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: HEALTH.2010.3.4-5 | Award Amount: 2.27M | Year: 2011

European health systems are committed to meeting the challenge of understanding the needs of migrant populations and adapting their services to meet these needs. The difficulties inextricably linked to this challenge are caused by the complexity of migration patterns and the differences between migrant population across EU countries. At present, the limited available data show that attempts to incorporate migrants health needs, in particular those of migrants from non-EU countries, into EU health systems have remained scattered and uncoordinated. COHEMIs general objective is to coordinate referral centres dealing with specific Latin American (LA) diseases in order to provide a clear understanding of the full migration cycle in relation with the health systems in Europe and Latin America and to provide a in-depth insight into priority health-related aspects of LA migration in order to facilitate the development of and transfer of evidence and information relevant to migrant health policies.


Patent
Cayetano Heredia Peruvian University and San Fernando S.A. | Date: 2015-01-07

The invention is referring to an essential oil from lemon peel useful as growth promoter in poultry, such composition comprises at least 16.84 to 46.12 % of D-Limonene; 5.67 to 19.86 % of y-Terpinene; 4.27 to 12.13 % of Terpinolene; 4.60 to 14.75 % of p-Ment-1-en-8-ol; among other components. The invention also refers to a poultry food supplement, which comprises 1 kg per metric ton of food from such composition of essential oil.


Grant
Agency: GTR | Branch: MRC | Program: | Phase: Research Grant | Award Amount: 151.65K | Year: 2015

Studies in developed countries have demonstrated benefits to preventive care (diet modifications, exercise) among patients with diabetes. Despite this knowledge, patients often dont manage their diabetes properly. In a study that we conducted in Lima, 71% of subjects with diabetes were aware of their disease, 40% were receiving treatment, and only 7% had achieved therapeutic goals. In Latin America, diabetes has a great impact on the health system due to high costs of disease control (US$10.7 billion) and indirect costs (US$54.5 billion) related to loss of productivity, disability, and premature death. Payment for achieving therapeutic goals, or rewards, have been tested as a way to improve health. Several studies have shown the promise of this approach in encouraging and maintaining weight loss, which is an important way to control diabetes. One study found that paying people to lose weight led to significantly greater weight loss. In another study in which the payments were linked to the success of multiple members of a group achieving their weight loss goals, the participants not only lost more weight, but also maintained the weight loss. These results are intriguing, and suggest that the study of rewards in self-management of diabetes requires further research. The approach of paying people to achieve health-related goals has also worked in developing countries. For example, Juntos is a program in Peru that pays pregnant women and mothers to utilize certain health services. On study found that Juntos increased the probability that children in households met their weight-height goals. In addition, families that were part of Juntos were more likely to seek professional health assistance in case of any disease, and the pregnant women were more likely to have their delivery attended by a skilled professional. This type of program takes advantage of the strong family structures in Latin America, and brings an element of group responsibility to the improvement of health. The individual responsible for fulfilling the requirements is not only encouraged to be responsible because of an individual reward, but to improve the situation of the family. This highlights the potential to use responsibility to others to design more effective policies. In this project, our goal is to determine the effectiveness of two different economic reward programs in promoting preventive behaviors and improving the health of individuals with Type II diabetes in Peru. In addition to rewarding patients for their improved health outcomes, we will go one step further and evaluate a cash incentive for a family or friend supporter, an approach we believe has great potential and may be more effective. In our study, we will enroll diabetes patients and randomly assign them to one of three groups. In one group, patients will receive cash rewards if they achieve certain goals related to management of their diabetes. In a second group, patients and a family or friend supporter will both receive a cash reward if the patient achieves their diabetes management goals. This will allow us to test whether or not the element of responsibility to others improves the ability of the patient to achieve their goals. Finally, a third group will not receive any cash reward. This is the control group to which the other groups will be compared to measure success of our approaches. We expect that after nine months of rewards, patients will effectively improve the preventive behaviors. Six months later, we will also assess if these improvements have been maintained without the cash reward. If our study is successful, it could be a way to encourage people with diabetes to better manage their disease. While there are costs associated with this approach, it could save money in the long run by reducing the complications of diabetes that occur when people dont manage their disease.


Patent
Institute Of Recherche Pour Le Developpment and Cayetano Heredia Peruvian University | Date: 2013-07-02

The present invention relates to peptides and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus Leishmania, especially infection with a South American strain causing the American Tegumentary Leishmaniasis (ATL).

Loading Cayetano Heredia Peruvian University collaborators
Loading Cayetano Heredia Peruvian University collaborators